

AMC BROADGATE QUANT 1

As of 31 Mach 2025

OBJECTIVE

To efficiently harvest rewarded systematic risk premia in the market, while eliminating unrewarded risk exposures, allowing investors to earn higher returns per unit of risk.

INVESTMENT STRATEGY & PROCESS

The portfolio is based on Broadgate's Quantitative Multi-Factor Model. It focuses on the proper management of "factor exposures" as the main source of performance and looks through asset class decompositions to focus on underlying factor decomposition. It aims to invest in an equal-weighted portfolio of 40 equity names in developed markets, selected based on Broadgate's proprietary Multi-Factor model. The strategy aims to outperform the benchmark –MSCI World index— by following an allocation determined by the intensity of factors (Momentum, Value, Low Volatility, Quality and Growth). Factors are built in-house, using proprietary descriptors with high return explanatory powers and a unique weighting scheme that allocates dynamically among the factors. The portfolio is rebalanced monthly, and the methodology is continuously reviewed by Broadgate's quant research team.

PRODUCT CHARACTERISTICS

Product	> AMC Broadgate Quant 1
ISIN	> FRELU0003488
Issuer/ Guarantor	Exane Solutions Luxembourg (SA) / BNP Paribas Moody's: Aa3; S&P: A+; Fitch AA-
Underlying	 Broadgate Quant 1 Dynamic Portfolio
Actively Managed	Yes, by Broadgate Advisers
Maturity	➤ Open-End
Denomination	▶ 1'000 USD
Currency	▶ USD
Total Management Fees	 1.25% p.a. (i.e 0.25% to Exane Solutions and 1.00% to Broadgate Advisers) + 10% Performance fees based on high watermark over an initial hurdle of 107%
Liquidity	➤ Daily
Pricing Publication	➤ Telekurs, Bloomberg
NAV	➤ USD 1025.08 (as of March 31 st , 2025)

AMC Manager Comment

The strategy was down by 6.8% in March while MSCI World was down by 4.6%.

Attribution: Last month most sectors were down, led by *Information Technology* (-5.2%), *Communication Services* (-5.0%) and *Consumer Discretionary* (-4.0%). *Consumer Staples* (2.7%), *Utilities* (0.9%) and *Energy* (0.8%) were the only sectors to be up. Broadgate Quant mandate underperformed the market by -2.3%, due to negative allocation (-1.3%) and selection (-1.2%), part offset by currency effect (0.3%).

Negative allocation was mainly due to overweight *Information Technology* and underweight *Energy*. Negative selection mainly from Healthcare: *BoneSupport Holding* down -13.0%, *Intuitive Surgical* -15.5%, *Camurus* -5.1% and Information Technology sectors: *AppLovin* down -18.7% and *Arista Networks* -16.7%. Positive currency effect was mainly due to overweight *SEK*.

Factor Sensitivity (Beta): The current top style exposures are, by order, Momentum, Quality and Growth.

HISTORICAL PERFORMANCE

Cumulative Performance (basis USD)



Performance snapshot of the share class - Actual 15.09.21 - 31.03.25

		Quant 1*	World
Performance (%)	1 Month	-6.77	-4.64
	3 Months	-8.02	-2.14
	YTD	-8.02	-2.14
	Since Inception	2.51	16.02
Risk (ex-post)	Annualized Volatility (%)	18.04	16.39
	Correlation	0.91	
	Tracing Error (%)	7.45	
	Beta	1.00	
Risk/Return	Sharpe Ratio	0.05	0.24
	Information Ratio	-0.39	

AMC Broadgate Quant 1

Broadgate MSCI



AMC BROADGATE QUANT 1

As of 31 March 2025









Portfolio Contribution

Best Performers


Components	MTD Performance
COPART INC	7.48%
DASSAULT SYSTEMES SE	7.46%
NOVARTIS AG-REG	5.91%
S&P GLOBAL INC	4.44%
MOODY'S CORP	4.22%
EBAY INC	3.75%
INTUIT INC	2.54%
MERCK & CO. INC.	2.51%
IG GROUP HOLDINGS PLC	2.47%
JACK HENRY & ASSOCIATES INC	1.61%

Worst Performers


Components	MTD Performance
LULULEMON ATHLETICA INC	-22.58%
DECKERS OUTDOOR CORP	-19.77%
APPLOVIN CORP-CLASS A	-18.66%
ARISTA NETWORKS INC	-16.73%
INTUITIVE SURGICAL INC	-15.48%
BROADCOM INC	-14.11%
NVIDIA CORP	-13.23%
BONESUPPORT HOLDING AB	-12.99%
ELI LILLY & CO	-11.64%
FORTINET INC	-10.88%

Portfolio Allocations

Breakdown by Geography



Breakdown by Sector



For more Information:

Broadgate Advisers

Tel:+41 (0)22 316 0060 Email: Quant1@broadgate.ch Internet: https://broadgateadvisers.com/

BNP Paribas Suisse SA

Email: joris.maillet@bnpparibas.com

This document/communication may contain "Research" as defined under MFID II unbundling rules; any such Research is intended either (i) for those firms who are in scope of the MFID II unbundling rules and have signed up to a BNP Paribas Global Markets Research package, or (ii) for firms that are out of scope of the MFID II unbundling rules and therefore are not required to pay for Research under MFID II. Please note that it is your firm's responsibility to ensure that you do not view or use any Research in this document. If your firm has not signed up to a BNP Paribas Global Markets Research package, unless your firm is out of scope of the MFID II unbundling rules. This document may also be regarded as a minor non-monetary benefit (MNMB) and it is your firm's responsibility to consider its own regulatory obligations in relation to inducements and accepting MNMBs. This document is common than a carepting MNMBs. This document is common than a carepting MNMBs. This document is common than a carepting MNMBs. This document is submitted to selected recipients only and it may not be made available lin whole or its subsidiaries or statistics (collectively "ve" or "SMP Paribas". As confideratial document it is unbunded to selected recipients only and its received to the common than a carepting MNMBs. This document is not a recommendation to engage in any action, does not constitute or form any part of any offer to sell or issue and is not a solicitation of any offer to purchase any financial instrument, nor shall it or any part of the fort first on the fort of the MNMB paribas with the contract or investment decision. To the extent that any transaction is subsequently entered into upon such terms any may be agreed by the partition of the fact of the Schrift of the fort of the partition of the solicity of the solicity of the partition of any offer to purchase any financial instrument, nor shall it or any part of the or the fact of the partition of any offer to purchase any financial instrument, nor shall it or any part of